Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chengda Pharmaceuticals Co's enterprise value is ¥4,775.6 Mil.
Chengda Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.3 Mil. Therefore, Chengda Pharmaceuticals Co's EV-to-EBITDA for today is -16,354.79.
The historical rank and industry rank for Chengda Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:
SZSE:301201'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28648.34 Med: 18.61 Max: 82.52
Current: -16354.79
During the past 12 years, the highest EV-to-EBITDA of Chengda Pharmaceuticals Co was 82.52. The lowest was -28648.34. And the median was 18.61.
SZSE:301201's EV-to-EBITDA is ranked worse than 100% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.2
vs SZSE:301201: -16354.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Chengda Pharmaceuticals Co (SZSE:301201) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chengda Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:
Chengda Pharmaceuticals Co's share price for today is ¥35.04.
Chengda Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.023.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengda Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengda Pharmaceuticals Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengda Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chengda Pharmaceuticals Co's EV-to-EBITDA falls into.
Chengda Pharmaceuticals Co's current Enterprise Value is ¥4,775.6 Mil.
Chengda Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengda Pharmaceuticals Co (SZSE:301201) has a EV-to-EBITDA of -16,354.79 as of Aug. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chengda Pharmaceuticals Co. According to the industry distribution chart, Chengda Pharmaceuticals Co ranks #999999 out of 739 companies in the Drug Manufacturers industry.
Is Chengda Pharmaceuticals Co's EV-to-EBITDA too high?
Chengda Pharmaceuticals Co's current EV-to-EBITDA is -16,354.79. Based on the distribution chart, Chengda Pharmaceuticals Co ranks #999999 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chengda Pharmaceuticals Co ranks #999999 out of 739 companies for EV-to-EBITDA. This places Chengda Pharmaceuticals Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.20, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chengda Pharmaceuticals Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengda Pharmaceuticals Co's current EV-to-EBITDA is -16,354.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥30.44, compared to a current price of ¥35.04 — trading 15.1% above its estimated fair value. The current EV-to-EBITDA is -16,354.79. Chengda Pharmaceuticals Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current EV-to-EBITDA is -16,354.79 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥35.04 is trading 15.1% above its estimated GF Value™ of ¥30.44.
GuruFocus considers Chengda Pharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SZSE:301201:
EV-to-EBITDA: -16,354.79
GF Value™: ¥30.44 vs. price of ¥35.04 (15.1% above fair value)
No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
77GF Score
Get the complete analysis for SZSE:301201
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301201 has been successfully added to your 
